1 BACKGROUND Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for hematological diseases. The HSCT and the subsequent period of immunodeficiency entail a risk of severe adverse events, including infections, relapse, and graft-versus-host disease (GvHD).1 The stem cell graft is known to play an essential role in the complications mentioned above.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile